SV40 virus — LLMpedia

Contents

SV40 virus is a small, non-enveloped double-stranded DNA virus discovered in the 1950s during tissue culture work with rhesus macaque kidney cells used to produce poliovirus vaccines. The agent was identified by researchers at institutions such as the National Institutes of Health, University of Pittsburgh, and Baxter International-associated labs and quickly became central to studies at centers including Cold Spring Harbor Laboratory, Rockefeller University, and the Pasteur Institute. SV40 has been studied for its interactions with cellular pathways, tumorigenesis, and molecular tools, influencing work in laboratories associated with Harvard University, Massachusetts Institute of Technology, University of California, Berkeley, and Stanford University.

Discovery and history

SV40 was first isolated during passaging of poliovirus in primary kidney cells from Macaca mulatta at facilities linked to Warren S. and others producing early poliovirus vaccines for companies tied to Eli Lilly and Company and Wyeth. The discovery prompted investigations at government bodies such as the Food and Drug Administration, National Institutes of Health, and later Congressional hearings involving committees from the United States Congress. Key historical figures and laboratories included teams at University of Michigan, Johns Hopkins University, and researchers like Bernard N. Fields and others associated with the American Society for Microbiology who characterized SV40 biology. Debates over contaminated vaccine lots involved manufacturers such as Merck & Co. and regulatory changes influenced procurement policies at the World Health Organization and national public health institutes, affecting immunization programs in countries like United States, United Kingdom, France, and India.

SV40 belongs to the family Polyomaviridae and shares morphological traits with other small DNA viruses studied at centers like European Molecular Biology Laboratory and Max Planck Institute. Electron microscopy work at facilities such as Scripps Research and Weizmann Institute defined a non-enveloped icosahedral capsid primarily composed of the VP1 protein, with minor components VP2 and VP3 — findings corroborated by structural biology groups at European Synchrotron Radiation Facility and Argonne National Laboratory. Cryo-electron microscopy studies involving teams from University of Oxford and ETH Zurich resolved capsid symmetry consistent with other members compared by labs at NIH National Library of Medicine. Capsid assembly and virion stability studies were conducted in collaboration with researchers at Cold Spring Harbor Laboratory and EMBL-EBI.

SV40 carries a circular double-stranded DNA genome approximately 5.2 kilobase pairs, a subject of sequencing efforts at genomic centers such as Wellcome Sanger Institute, GenBank, and Broad Institute. The genome encodes early region proteins including large T antigen and small t antigen, and late region capsid proteins VP1, VP2, and VP3; these coding elements were characterized by teams at University of California, San Diego and Massachusetts General Hospital. Replication depends on host factors involving p53 and Retinoblastoma protein pathways elucidated through collaborations between investigators at Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. Molecular cloning and reporter assays conducted at Cold Spring Harbor Laboratory and Yale University helped map origins of replication and regulatory elements, with replication intermediates similarly analyzed by researchers at University of Cambridge and Imperial College London.

SV40 infects certain primate cells, with a documented host range primarily in simian hosts like rhesus macaque and some permissive human cell lines studied at NIH Clinical Center and academic hospitals such as Cleveland Clinic. The large T antigen can alter cell-cycle control by interacting with tumor suppressors characterized in studies at Memorial Sloan Kettering Cancer Center, Cold Spring Harbor Laboratory, and Fred Hutchinson Cancer Center, contributing to transformation in cultured cells used at University of Wisconsin–Madison and University of Texas Southwestern Medical Center. Oncogenic potential was examined in animal models at institutions like National Cancer Institute and laboratories linked to Salk Institute and Johns Hopkins University School of Medicine. Clinical associations and controversy over human disease links led to epidemiological and pathology investigations at Mayo Clinic, Centers for Disease Control and Prevention, and university pathology departments across United States, Italy, and Japan.

SV40 large T antigen is a cornerstone reagent in molecular biology, used to immortalize cell lines at laboratories including ATCC, European Collection of Authenticated Cell Cultures, and research centers such as Broad Institute. SV40-derived vectors and origin-of-replication elements have been exploited in cloning systems developed at Addgene, Rosetta groups, and gene expression studies at Howard Hughes Medical Institute-affiliated labs. Pioneering studies employing SV40 informed technologies used at Genentech, Novartis, and biotech incubators in Cambridge, Massachusetts and Silicon Valley. SV40 reagents are common in virology courses at Johns Hopkins University, UCLA, and Columbia University and in structural analysis projects at Lawrence Berkeley National Laboratory.

Historical contamination of polio vaccine stocks raised public health responses involving agencies like the World Health Organization, Food and Drug Administration, and Centers for Disease Control and Prevention, prompting policy reviews at national ministries of health in United States, France, and India. Surveillance and seroepidemiological studies were conducted by teams at Johns Hopkins Bloomberg School of Public Health, London School of Hygiene & Tropical Medicine, and Karolinska Institutet, while cancer epidemiology centers such as International Agency for Research on Cancer and National Cancer Institute evaluated associations with human tumors. Debates over causality led to systematic reviews involving researchers at Cochrane Collaboration and meta-analyses performed by groups affiliated with University of Toronto and McGill University. Regulatory outcomes influenced vaccine manufacturing standards overseen by bodies like the European Medicines Agency and national regulatory agencies, with long-term monitoring programs at public health institutes in Australia, Canada, and Germany.